JPRN-jRCT2080222103未知3 期
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE)
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Have completed 52 weeks of treatment in BCDS study
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE)Systemic Lupus Erythematosus (SLE)MedDRA version: 16.0Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859EUCTR2010-022101-18-HUEli Lilly and Company1,276
进行中（未招募）
1 期
The study will test an experimental drug called B/F/TAF (bictegravir/emtricitabine/tenofovir alafenamide) fixed-dose combination (FDC) for the treatment of HIV-1 infection. The purpose of this study is to evaluate the effectiveness of switching to B/F/TAF FDC in HIV-1 infected adults aged = 65 years who are virologically suppressed (HIV-1 RNA test <50 copies/mL) currently on elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide FDC or tenofovir disoproxil fumarate containing regimens.Human Immunodeficiency Virus (HIV-1) InfectionMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2017-003428-61-ESGilead Sciences, Inc.86
进行中（未招募）
不适用
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA)MedDRA version: 12.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2010-022208-36-DEEli Lilly and Company1,505
进行中（未招募）
不适用
Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE).Systemic Lupus Erythematosus (SLE)MedDRA version: 17.0Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859EUCTR2010-022101-18-HREli Lilly and Company1,276
进行中（未招募）
不适用
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA)MedDRA version: 12.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2010-022208-36-LTEli Lilly and Company1,505